Vivian Bykerk, MD, associate attending rheumatologist at the Hospital for Special Surgery, associate professor of medicine at Weill Cornell Medical College, discusses switching patients to biosimilars.
Transcript:
How are your patients responding to the idea of switching to a biosimilar from a reference biologic?
So, I think a person who’s barely controlled…I wouldn’t switch them, because I don’t know what’s going to happen. A person who is incredibly well controlled, I suspect there will be no problem. A person who’s on methotrexate and well controlled, where I suspect methotrexate is doing half the work, again, I don’t have any concern.
But, there are people who can’t use methotrexate, who are sort of hovering at the low disease activity mark and sometimes flare, but mostly they’re doing quite well. I wouldn’t switch those people, I wouldn’t touch them. So, I think that everyone needs to have some consensus about where it’s okay, where it’s possible, and where you just don’t change anything.
I think that, at this point, I know the insurance companies and the pharmacy benefit managers believe they are making good decisions for our patients, but they need to include the patient’s rheumatologist in the decision.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.